Chat with us, powered by LiveChat

Loading...

Continuous Glucose Monitoring Devices Market Report

RA08925

Continuous Glucose Monitoring Devices Market by Component (Sensors, Transmitters, and Receivers), End-use (Hospitals, Home Care, and Others), Connectivity (Bluetooth and 4G), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032

RA08925

Pages: 270

Oct 2023

Continuous Glucose Monitoring Devices Overview

A continuous glucose monitoring device is a small wearable device that helps people with diabetes manage their blood sugar levels more effectively. It constantly measures glucose levels in the body's interstitial fluid and provides real-time data to the user. This allows individuals to track their glucose trends and receive alerts for high or low levels and make timely adjustments to their diet and medication or activities. The continuous glucose monitoring devices market has experienced substantial growth due to increasing diabetes cases and the demand for better diabetes management tools. Key players in the market offer a variety of continuous glucose monitoring devices, ranging from standalone devices to those integrated with insulin pumps. These devices use sensors to monitor glucose levels, with data often sent to smartphone apps or dedicated receivers. The continuous glucose monitoring devices market is driven by technological advancements, the need for non-invasive monitoring, and improved patient outcomes. While costs and insurance coverage can be factors influencing adoption, the convenience and potential to enhance diabetes management have contributed to the rising popularity of continuous glucose monitoring devices. 

Global Continuous Glucose Monitoring Devices Market Analysis

The global continuous glucose monitoring devices market size was $7,334.3 million in 2022 and is predicted to grow with a CAGR of 21.6%, by generating a revenue of $51,622.7 million by 2032.

COVID-19 Impact on Global Continuous Glucose Monitoring Devices Market

The COVID-19 pandemic significantly affected the continuous glucose monitoring (CGM) devices market. Lockdowns, disrupted supply chains, and shifts in healthcare priorities led to both challenges and opportunities for the industry. CGM device manufacturers faced production delays and logistic issues, impacting the availability of these devices for patients. Many individuals hesitated to visit healthcare facilities, affecting the adoption of new CGM devices. However, the pandemic highlighted the importance of remote patient monitoring, boosting the interest in CGM technology. The convenience of tracking glucose levels at home gained traction, spurring innovation in the continuous glucose monitoring devices sector. Some companies adapted by enhancing telehealth integration and developing user-friendly apps for data analysis. As the world recovers, the CGM market is expected to rebound, driven by increasing diabetes cases and a growing focus on personal health. Balancing supply chain resilience with evolving healthcare demands will remain a key challenge for CGM device manufacturers in the post-pandemic landscape.

Rising Use of Continuous Glucose Monitoring (CGM) Devices for Diabetes Management to Drive the Market Growth

Continuous glucose monitoring devices offer several benefits for individuals managing diabetes. These devices provide real-time insights into blood sugar levels, helping users make informed decisions about their diet, exercise, and medication. Unlike traditional fingerstick tests, CGM eliminates the need for frequent pricking, enhancing comfort and convenience. CGM devices offer trend data that show how blood sugar levels change over time, highlighting patterns that might have gone unnoticed. This aids in adjusting insulin dosages and preventing severe fluctuations. Moreover, CGM alarms notify users of dangerously high or low levels, offering peace of mind and the ability to take prompt action. For diabetics, CGM fosters a deeper understanding of how lifestyle choices affect glucose levels, encouraging healthier habits. CGM data can be shared with healthcare providers, enabling more personalized treatment plans. Furthermore, continuous data collection aids in recognizing nocturnal hypoglycemia, enhancing safety during sleep. In summary, CGM devices empower individuals to proactively manage their diabetes by providing real-time data, reducing discomfort, aiding in pattern recognition, promoting healthier choices, and facilitating better communication with healthcare professionals.

Challenges and Considerations associated with Continuous Glucose Monitoring (CGM) Devices to Restrain the Market Growth

Continuous glucose monitoring (CGM) devices offer valuable insights for individuals managing diabetes, but they come with some drawbacks. These include discomfort due to the insertion process and the device itself, potential skin irritation or allergies, and the need for frequent calibrations to ensure accuracy. Users might also face challenges with the device's accuracy, as it can sometimes provide incorrect readings, leading to incorrect treatment decisions. Privacy concerns arise since the device collects sensitive health data that could be vulnerable to breaches. CGM devices require regular maintenance, involving battery changes or recharging, and the possibility of device malfunctions. They can be costly, straining individuals who lack adequate insurance coverage or financial resources. Moreover, dependence on technology might result in reduced awareness of one's body signals, undermining the development of self-awareness about glucose levels.

Advancements in Continuous Glucose Monitoring Devices to Drive Excellent Opportunities for Future

Future opportunities for continuous glucose monitoring devices include improved accuracy and reliability, enhanced user experience, expanded compatibility with various platforms, integration with other health monitoring technologies, and cost reduction. These devices can capitalize on advancements in AI and machine learning to refine their algorithms, resulting in more precise glucose level predictions. This will lead to better disease management and increased patient trust. Additionally, there is room for enhancing the comfort and convenience of wearing these devices, making them more wearable and discreet. Collaborations with smartphone manufacturers and health apps could facilitate seamless data sharing and analysis. Integration with insulin pumps and other health devices can create a comprehensive health management ecosystem. The potential to extend continuous glucose monitoring beyond diabetes to other health conditions, like fitness optimization, offers another avenue for growth. Regulatory approvals and endorsements from healthcare professionals will further solidify their credibility. Overall, continuous glucose monitoring devices have a promising future in advancing health management through technological innovation.

Global Continuous Glucose Monitoring Devices Market, by Component, 2022

The sensors sub-segment accounted for the highest market share in 2022. Sensors hold a central role in continuous glucose monitoring devices due to their ability to directly measure glucose levels in the body. These sensors are pivotal in providing real-time data, allowing individuals to monitor their blood sugar without the need for frequent and invasive procedures like traditional finger pricking. The dominance of sensors is owed to their precision and reliability in capturing glucose fluctuations, aiding in the timely detection of high or low blood sugar levels. This empowers individuals to make prompt and informed decisions about their diet, medication, and activities. The sensor technology has advanced significantly, offering improved accuracy and reduced calibration requirements, further enhancing the user experience. In essence, sensors are the linchpin of continuous glucose monitoring, offering an accessible and user-friendly way for people to manage their diabetes effectively and lead healthier lives.

  Global Continuous Glucose Monitoring Devices Market, by End-use, 2022

The home care sub-segment accounted for the highest market share in 2022. Home care has emerged as the primary user of continuous glucose monitoring devices due to their practicality and user-friendly nature. These devices offer individuals the convenience of tracking their blood sugar levels around the clock without the need for frequent hospital visits. The technology non-invasive or minimally invasive nature makes it more appealing and provides real-time data that helps users make timely adjustments to their lifestyle and medication. The CGM devices user-friendliness and compact size and ease of use have made them a staple for those managing diabetes at home. They empower individuals to take charge of their health and make informed decisions without relying solely on medical professionals. The clear and accessible insights provided by CGMs promote a better understanding of how various factors influence blood glucose levels and contribute to improved diabetes management. In conclusion, the dominance of CGM devices in the home care setting can be attributed to their convenience, ease of use, and the valuable insights they provide for effective diabetes management. 

  Global Continuous Glucose Monitoring Devices Market, by Connectivity, 2022

The Bluetooth sub-segment accounted for the highest market share in 2022. Bluetooth has emerged as the dominant connectivity choice for continuous glucose monitoring devices due to its widespread compatibility and reliability. Its seamless integration with smartphones and other devices allows users to conveniently monitor their glucose levels and receive real-time updates. Bluetooth's low energy consumption ensures that the monitoring device can operate for extended periods without frequent battery replacements. Its robust and secure communication protocols protect sensitive health data, providing peace of mind to users. Bluetooth's well-established technology infrastructure simplifies the development process for manufacturers, resulting in quicker and more cost-effective product releases. The user-friendly nature of Bluetooth, coupled with its broad adoption, makes it an ideal choice for continuous glucose monitoring devices, enabling individuals to manage their health with greater ease and efficiency.

Global Continuous Glucose Monitoring Devices Market Share, by Region, 2022

The North America continuous glucose monitoring devices market generated the highest revenue in 2022. Firstly, the presence of advanced healthcare infrastructure and a strong research environment has facilitated the development and early adoption of such technologies. Additionally, a higher prevalence of diabetes in North America has driven the demand for effective glucose monitoring solutions, prompting both patients and healthcare professionals to embrace CGM devices. Moreover, the region's regulatory framework and reimbursement policies have played a role in fostering the growth of CGM usage. Accessible insurance coverage and streamlined regulatory pathways have made it more feasible for individuals to incorporate these devices into their diabetes management routines. Cultural aspects such as a proactive approach to health and technological innovation have also contributed to the dominance of CGM adoption in North America. Awareness and acceptance of wearable health tech, along with a willingness to invest in personal well-being, have further accelerated the integration of CGM devices into daily life.

Competitive Scenario in the Global Continuous Glucose Monitoring Devices Market

Agreement and investment are the two key strategies opted by the operating companies in this market. Some of the leading companies in the global market are F. Hoffmann-La Roche Ltd., Dexcom Inc., Abbott Laboratories, Medtronic Inc., Ypsomed AG, GlySens Incorporated, Ascensia Diabetes Care, A. Menarini Diagnostics, Johnson & Johnson, and Senseonics Holdings, Inc.

Aspect

Particular

Historical Market Estimations

2020-2022

Base Year for Market Estimation

2022

Forecast Timeline for Market Projection

2023-2032

Geographical Scope

North America, Europe, Asia-Pacific, and LAMEA

Segmentation by Component

  • Sensors
  • Transmitters
  • Receivers

Segmentation by End-use

  • Hospitals
  • Home Care
  • Others

Segmentation by Connectivity

  • Bluetooth
  • 4G

Key Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • Dexcom Inc.
  • Abbott Laboratories
  • Medtronic Inc.
  • Ypsomed AG
  • GlySens Incorporated
  • Ascensia Diabetes Care
  • A. Menarini Diagnostics
  • Johnson & Johnson
  • Senseonics Holdings, Inc.

Frequently Asked Questions
 

A. The size of the global continuous glucose monitoring devices market was over $7,334.3 million in 2022 and is projected to reach $51,622.7 million by 2032.

A. Abbott Laboratories, Medtronic Inc., Ypsomed AG, and GlySens Incorporated are the major companies in the continuous glucose monitoring devices market.

A. Agreement and investment are the two key strategies opted by the operating companies in this market.

A. Abbott Laboratories, Medtronic Inc., Ypsomed AG, and GlySens Incorporated are investing more on R&D practices.

1.    Research Methodology
1.1.    Desk Research
1.2.    Real time insights and validation
1.3.    Forecast model.
1.4.    Assumptions and forecast parameters
1.5.    Market size estimation
1.5.1.    Top-down approach
1.5.2.    Bottom-up approach
2.    Report Scope
2.1.    Market definition
2.2.    Key objectives of the study
2.3.    Report overview
2.4.    Market segmentation
2.5.    Overview of the impact of COVID-19 on continuous glucose monitoring devices market.
3.    Executive Summary
4.    Market Overview
4.1.    Introduction
4.2.    Growth impact forces
4.2.1.    Drivers
4.2.2.    Restraints
4.2.3.    Opportunities
4.3.    Market value chain analysis
4.3.1.    List of raw material suppliers
4.3.2.    List of manufacturers 
4.3.3.    List of distributors
4.4.    Innovation & sustainability matrices
4.4.1.    Technology matrix
4.4.2.    Regulatory matrix
4.5.    Porter’s five forces analysis
4.5.1.    Bargaining power of suppliers
4.5.2.    Bargaining power of consumers
4.5.3.    Threat of substitutes
4.5.4.    Threat of new entrants
4.5.5.    Competitive rivalry intensity
4.6.    PESTLE analysis
4.6.1.    Political
4.6.2.    Economical
4.6.3.    Social
4.6.4.    Technological
4.6.5.    Environmental
4.7.    Impact of COVID-19 on continuous glucose monitoring devices market
4.7.1.    Pre-covid market scenario
4.7.2.    Post-covid market scenario
5.     Continuous Glucose Monitoring Devices Market, by Component 
5.1.    Overview
5.2.    Sensors
5.2.1.    Definition, key trends, growth factors, and opportunities
5.2.2.    Market size analysis, by region, 2022-2032
5.2.3.    Market share analysis, by country, 2022-2032
5.3.    Transmitters
5.3.1.    Definition, key trends, growth factors, and opportunities
5.3.2.    Market size analysis, by region, 2022-2032
5.3.3.    Market share analysis, by country, 2022-2032
5.4.    Receivers
5.4.1.    Definition, key trends, growth factors, and opportunities
5.4.2.    Market size analysis, by region, 2022-2032
5.4.3.    Market share analysis, by country, 2022-2032
5.5.    Research Dive Exclusive Insights
5.5.1.    Market attractiveness
5.5.2.    Competition heatmap
6.    Continuous Glucose Monitoring Devices Market, by Vertical 
6.1.    Overview
6.2.    Hospitals
6.2.1.    Definition, key trends, growth factors, and opportunities
6.2.2.    Market size analysis, by region, 2022-2032
6.2.3.    Market share analysis, by country, 2022-2032
6.3.    Home Care
6.3.1.    Definition, key trends, growth factors, and opportunities
6.3.2.    Market size analysis, by region, 2022-2032
6.3.3.    Market share analysis, by country, 2022-2032
6.4.    Others
6.4.1.    Definition, key trends, growth factors, and opportunities
6.4.2.    Market size analysis, by region, 2022-2032
6.4.3.    Market share analysis, by country, 2022-2032
6.5.    Research Dive Exclusive Insights
6.5.1.    Market attractiveness
6.5.2.    Competition heatmap
7.        Continuous Glucose Monitoring Devices Market, by Connectivity 
7.1.    Overview
7.2.    Bluetooth
7.2.1.    Definition, key trends, growth factors, and opportunities
7.2.2.    Market size analysis, by region, 2022-2032
7.2.3.    Market share analysis, by country, 2022-2032
7.3.    4G
7.3.1.    Definition, key trends, growth factors, and opportunities
7.3.2.    Market size analysis, by region, 2022-2032
7.3.3.    Market share analysis, by country, 2022-2032
7.4.    Research Dive Exclusive Insights
7.4.1.    Market attractiveness
7.4.2.    Competition heatmap
8.    Continuous Glucose Monitoring Devices Market, by Region
8.1.    North America
8.1.1.    U.S.
8.1.1.1.    Market size analysis, by End Use
8.1.1.2.    Market size analysis, by Connectivity 
8.1.2.    Canada
8.1.2.1.    Market size analysis, by End Use
8.1.2.2.    Market size analysis, by Connectivity
8.1.3.    Mexico
8.1.3.1.    Market size analysis, by End Use
8.1.3.2.    Market size analysis, by Connectivity
8.1.4.    Research Dive Exclusive Insights
8.1.4.1.    Market attractiveness
8.1.4.2.    Competition heatmap
8.2.    Europe
8.2.1.    Germany 
8.2.1.1.    Market size analysis, by End Use
8.2.1.2.    Market size analysis, by Connectivity
8.2.2.    UK
8.2.2.1.    Market size analysis, by End Use
8.2.2.2.    Market size analysis, by Connectivity
8.2.3.    France
8.2.3.1.    Market size analysis, by End Use
8.2.3.2.    Market size analysis, by Connectivity
8.2.4.    Spain
8.2.4.1.    Market size analysis, by End Use
8.2.4.2.    Market size analysis, by Connectivity
8.2.5.    Italy
8.2.5.1.    Market size analysis, by End Use
8.2.5.2.    Market size analysis, by Connectivity
8.2.6.    Rest of Europe
8.2.6.1.    Market size analysis, by End Use
8.2.6.2.    Market size analysis, by Connectivity
8.2.7.    Research Dive Exclusive Insights
8.2.7.1.    Market attractiveness
8.2.7.2.    Competition heatmap
8.3.    Asia Pacific
8.3.1.    China
8.3.1.1.    Market size analysis, by End Use
8.3.1.2.    Market size analysis, by Connectivity
8.3.2.    Japan 
8.3.2.1.    Market size analysis, by End Use
8.3.2.2.    Market size analysis, by Connectivity
8.3.3.    India
8.3.3.1.    Market size analysis, by End Use
8.3.3.2.    Market size analysis, by Connectivity
8.3.4.    Australia
8.3.4.1.    Market size analysis, by End Use
8.3.4.2.    Market size analysis, by Connectivity
8.3.5.    South Korea
8.3.5.1.    Market size analysis, by End Use
8.3.5.2.    Market size analysis, by Connectivity
8.3.6.    Rest of Asia Pacific
8.3.6.1.    Market size analysis, by End Use
8.3.6.2.    Market size analysis, by Connectivity
8.3.7.    Research Dive Exclusive Insights
8.3.7.1.    Market attractiveness
8.3.7.2.    Competition heatmap
8.4.    LAMEA
8.4.1.    Brazil
8.4.1.1.    Market size analysis, by End Use
8.4.1.2.    Market size analysis, by Connectivity
8.4.2.    Saudi Arabia
8.4.2.1.    Market size analysis, by End Use
8.4.2.2.    Market size analysis, by Connectivity
8.4.3.    UAE
8.4.3.1.    Market size analysis, by End Use
8.4.3.2.    Market size analysis, by Connectivity
8.4.4.    South Africa
8.4.4.1.    Market size analysis, by End Use
8.4.4.2.    Market size analysis, by Connectivity
8.4.5.    Rest of LAMEA
8.4.5.1.    Market size analysis, by End Use
8.4.5.2.    Market size analysis, by Connectivity
8.4.6.    Research Dive Exclusive Insights
8.4.6.1.    Market attractiveness
8.4.6.2.    Competition heatmap
9.    Competitive Landscape
9.1.    Top winning strategies, 2022
9.1.1.    By strategy
9.1.2.    By year
9.2.    Strategic overview
9.3.    Market share analysis, 2022
10.    Company Profiles
10.1.    F. Hoffmann-La Roche Ltd.
10.1.1.    Overview
10.1.2.    Business segments
10.1.3.    Product portfolio
10.1.4.    Financial performance
10.1.5.    Recent developments
10.1.6.    Audi
10.2.    Dexcom Inc.
10.2.1.    Overview
10.2.2.    Business segments
10.2.3.    Product portfolio
10.2.4.    Financial performance
10.2.5.    Recent developments
10.2.6.    SWOT analysis
10.3.    Abbott Laboratories  
10.3.1.    Overview
10.3.2.    Business segments
10.3.3.    Product portfolio
10.3.4.    Financial performance
10.3.5.    Recent developments
10.3.6.    SWOT analysis
10.4.    Medtronic Inc.
10.4.1.    Overview
10.4.2.    Business segments
10.4.3.    Product portfolio
10.4.4.    Financial performance
10.4.5.    Recent developments
10.4.6.    SWOT analysis
10.5.    Ypsomed AG. 
10.5.1.    Overview
10.5.2.    Business segments
10.5.3.    Product portfolio
10.5.4.    Financial performance
10.5.5.    Recent developments
10.5.6.    SWOT analysis
10.6.    GlySens Incorporated 
10.6.1.    Overview
10.6.2.    Business segments
10.6.3.    Product portfolio
10.6.4.    Financial performance
10.6.5.    Recent developments
10.6.6.    SWOT analysis
10.7.    Ascensia Diabetes Care.  
10.7.1.    Overview
10.7.2.    Business segments
10.7.3.    Product portfolio
10.7.4.    Financial performance
10.7.5.    Recent developments
10.7.6.    SWOT analysis
10.8.    A. Menarini Diagnostics
10.8.1.    Overview
10.8.2.    Business segments
10.8.3.    Product portfolio
10.8.4.    Financial performance
10.8.5.    Recent developments
10.8.6.    SWOT analysis
10.9.    Johnson & Johnson  
10.9.1.    Overview
10.9.2.    Business segments
10.9.3.    Product portfolio
10.9.4.    Financial performance
10.9.5.    Recent developments
10.9.6.    SWOT analysis
10.10.    Senseonics Holdings, Inc.
10.10.1.    Overview
10.10.2.    Business segments
10.10.3.    Product portfolio
10.10.4.    Financial performance
10.10.5.    Recent developments
10.10.6.    SWOT analysis

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed